Israel's major research universities run technology transfer through dedicated for-profit subsidiaries — Yissum at the Hebrew University of Jerusalem, Yeda at the Weizmann Institute of Science, and Ramot at Tel Aviv University — a structure the research-management reference body CASRAI has documented as a distinct national model.

The model matters to R&D managers for one reason: it changes who you negotiate with. In this system, the university itself does not hold or license intellectual property from its labs. A wholly owned commercial subsidiary does, and that subsidiary operates with a corporate mandate, its own staff and its own revenue targets. For corporate R&D and venture portfolio teams, that means licensing discussions, material transfer agreements and spin-out formation run through a commercial counterparty rather than a university administration office.

CASRAI, which maintains standard research-administration terminology and practice descriptions, has published an overview of this framework under the title "Israel's Tech Transfer Model: Yissum, Yeda, Ramot, and For-Profit University Subsidiaries."

Why does the subsidiary structure matter?

The core distinction is legal and financial. A for-profit subsidiary can:

• hold equity in spin-out companies formed around university inventions;
• enter exclusive and non-exclusive licensing deals as a commercial entity;
• reinvest licensing revenue into further technology development and patent costs;
• operate at market speed, without public-procurement rules that constrain the university itself.

Each of the three named organizations anchors a different institution. Yissum serves the Hebrew University of Jerusalem. Yeda serves the Weizmann Institute of Science. Ramot serves Tel Aviv University. Together they cover the three largest research universities by research output in the country, and their licensing activity has been a routine channel for pharmaceutical, agritech and software partnerships.

What does this change for researchers and their managers?

For principal investigators, the practical consequence lands at the point of disclosure. Invention disclosures, patent filing decisions and industry negotiations route through the subsidiary, not through an internal faculty committee. Researchers typically receive a share of net licensing revenue under a fixed institutional formula, a point any lab should verify before signing an agreement, since the split determines personal upside from a spin-out.

For corporate R&D directors, the model compresses deal timelines but introduces a different diligence question. Because the subsidiary is a company, exclusivity terms, field-of-use restrictions and equity positions in spin-outs follow commercial norms. Portfolio managers evaluating an Israeli university spin-out should expect the subsidiary on the cap table alongside the founders.

How solid is the underlying information?

Caveats apply. The source item available to Hypothesis Wire is a reference entry, not a study. It contains no sample data, no revenue figures and no licensing statistics, and CASRAI's role is descriptive standardization rather than evaluation. Readers should treat the structural description above as documented, and treat any performance claims about the model — hit rates, income per institution, spin-out survival — as absent from this source until a dataset is published.

The comparison point for benchmarking remains the US Bayh-Dole system, where universities license directly through internal offices. Whether the subsidiary structure outperforms it in revenue per research dollar is an empirical question the reference entry does not answer.

What comes next?

CASRAI's entry signals that the Israeli subsidiary model is now treated as a standardized, named category in research administration practice — and R&D managers structuring university partnerships in Israel should expect the Yissum, Yeda and Ramot entities, not the universities, as their contracting counterparties going forward.